0000000001092764

AUTHOR

Elmar Jaeckel

showing 2 related works from this author

HCV-induced immune responses influence the development of operational tolerance after liver transplantation in humans.

2014

Pathogen-induced immune responses prevent the establishment of transplantation tolerance in experimental animal models. Whether this occurs in humans as well remains unclear. The development of operational tolerance in liver transplant recipients with chronic hepatitis C virus (HCV) infection allows us to address this question. We conducted a clinical trial of immunosuppression withdrawal in HCV-infected adult liver recipients to elucidate (i) the mechanisms through which allograft tolerance can be established in the presence of an ongoing inflammatory response and (ii) whether anti-HCV heterologous immune responses influence this phenomenon. Of 34 enrolled liver recipients, drug withdrawal…

Graft RejectionMaleHepatitis C virusT cellmedicine.medical_treatmentHepacivirusLiver transplantationCD8-Positive T-Lymphocytesmedicine.disease_causeImmune systemInterferonmedicineImmune ToleranceHumansLymphocyte CountImmunosuppression Therapybusiness.industryImmunityImmunosuppressionReceptors Antigen T-Cell gamma-deltaGeneral MedicineMiddle Agedmedicine.diseaseLiver TransplantationTransplantationmedicine.anatomical_structureGene Expression RegulationImmunologyInterferon Type IFemaleViral hepatitisbusinessBiomarkersmedicine.drugScience translational medicine
researchProduct

Early monotherapy with pegylated interferon alpha-2b for acute hepatitis C infection: the HEP-NET acute-HCV-II study.

2006

Early treatment of acute hepatitis C with interferon alpha-2b for 24 weeks prevents chronic infection in almost all patients. Because pegylated interferons have replaced conventional interferon in the therapy of chronic hepatitis C, the aim of this study was to analyze the efficacy of an early treatment of acute hepatitis C with peginterferon alpha-2b. Between February 2001 and February 2004, 89 individuals with acute HCV infection were recruited at 53 different centers in Germany. Patients received 1.5 microg/kg peginterferon alpha-2b for 24 weeks; treatment was initiated after a median of 76 days after infection (range 14-150). End-of-treatment response and sustained virological response …

AdultMalemedicine.medical_specialtyTime FactorsAdolescentmedicine.medical_treatmentPegylated interferon alpha-2b610 MedizinInterferon alpha-2GastroenterologyPolyethylene GlycolsInterferonInternal medicineMedicineHumansAgedHepatologybusiness.industryInterferon-alphaMiddle AgedHepatitis CRecombinant ProteinsClinical trialChronic infectionCytokineImmunologyAcute DiseasePopulation studyPatient ComplianceFemaleViral diseaseAcute hepatitis Cbusinessmedicine.drugHepatology (Baltimore, Md.)
researchProduct